<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37577714</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.07.27.23293177</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.07.27.23293177</ELocationID><Abstract><AbstractText>The etiologic mechanisms of post-acute medical morbidities and unexplained symptoms (Long COVID) following SARS-CoV-2 infection are incompletely understood. There is growing evidence that viral persistence and immune dysregulation may play a major role. We performed whole-body positron emission tomography (PET) imaging in a cohort of 24 participants at time points ranging from 27 to 910 days following acute SARS-CoV-2 infection using a novel radiopharmaceutical agent, [<sup>18</sup>F]F-AraG, a highly selective tracer that allows for anatomical quantitation of activated T lymphocytes. Tracer uptake in the post-acute COVID group, which included those with and without Long COVID symptoms, was significantly higher compared to pre-pandemic controls in many anatomical regions, including the brain stem, spinal cord, bone marrow, nasopharyngeal and hilar lymphoid tissue, cardiopulmonary tissues, and gut wall. Although T cell activation tended to be higher in participants imaged closer to the time of the acute illness, tracer uptake was increased in participants imaged up to 2.5 years following SARS-CoV-2 infection. We observed that T cell activation in spinal cord and gut wall was associated with the presence of Long COVID symptoms. In addition, tracer uptake in lung tissue was higher in those with persistent pulmonary symptoms. Notably, increased T cell activation in these tissues was also observed in many individuals without Long COVID. Given the high [<sup>18</sup>F]F-AraG uptake detected in the gut, we obtained colorectal tissue for <i>in situ</i> hybridization SARS-CoV-2 RNA and immunohistochemical studies in a subset of participants with Long COVID symptoms. We identified cellular SARS-CoV-2 RNA in rectosigmoid lamina propria tissue in all these participants, ranging from 158 to 676 days following initial COVID-19 illness, suggesting that tissue viral persistence could be associated with long-term immunological perturbations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryder</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flavell</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yingbing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levi</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CellSight Technologies, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaFranchi</LastName><ForeName>Brian H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveau</LastName><ForeName>Tyler-Marie</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asare</LastName><ForeName>Kofi A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslam</LastName><ForeName>Maya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Wally</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szabo</LastName><ForeName>Gyula</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deswal</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buitrago</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Viva</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrestha</LastName><ForeName>Uttam</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalhuisen</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Nitasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambir</LastName><ForeName>Aruna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CellSight Technologies, San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somsouk</LastName><ForeName>Ma</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Youngho</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laszik</LastName><ForeName>Zoltan G</ForeName><Initials>ZG</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VanBrocklin</LastName><ForeName>Henry F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI158013</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI145806</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI126521</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI146268</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PET imaging</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immune activation</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 (PASC)</Keyword><Keyword MajorTopicYN="N">viral persistence</Keyword></KeywordList><CoiStatement>Conflicts of Interest MJP reports consulting fees for Gilead Sciences and AstraZeneca, outside the submitted work. TJH reports consulting fees for Roche and Regeneron outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37577714</ArticleId><ArticleId IdType="pmc">PMC10418298</ArticleId><ArticleId IdType="doi">10.1101/2023.07.27.23293177</ArticleId><ArticleId IdType="pii">2023.07.27.23293177</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27(4):601&#x2013;615. DOI: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023;21(3):133&#x2013;146. DOI: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021;594(7862):259&#x2013;264. DOI: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention COVID Data Tracker. US Department of Health and Human Services, CDC. (https://covid.cdc.gov/covid-data-tracker).</Citation></Reference><Reference><Citation>Robertson MM, Qasmieh SA, Kulkarni SG, et al. The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis 2023;76(9):1636&#x2013;1645. DOI: 10.1093/cid/ciac961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac961</ArticleId><ArticleId IdType="pubmed">36542514</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol 2022;43(4):268&#x2013;270. DOI: 10.1016/j.it.2022.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res 2021. DOI: 10.1016/j.trsl.2021.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.11.006</ArticleId><ArticleId IdType="pmc">PMC8588584</ArticleId><ArticleId IdType="pubmed">34780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26(10):1636&#x2013;1643. DOI: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020;584(7821):463&#x2013;469. DOI: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022;185(5):881&#x2013;895 e20. DOI: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Kelly JD, et al. Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight 2022;7(10). DOI: 10.1172/jci.insight.157053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157053</ArticleId><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB, Peluso MJ, Ding J, et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-kappaB signaling. JCI Insight 2022;7(18). DOI: 10.1172/jci.insight.164813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.164813</ArticleId><ArticleId IdType="pmc">PMC9675436</ArticleId><ArticleId IdType="pubmed">36134654</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 2021;36(6):109518. DOI: 10.1016/j.celrep.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 2021;224(11):1839&#x2013;1848. DOI: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Sans HM, Forman CA, et al. Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. Neurol Neuroimmunol Neuroinflamm 2022;9(5). DOI: 10.1212/NXI.0000000000200003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv 2022. DOI: 10.1101/2022.08.09.22278592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Fong SW, Young BE, et al. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infect Dis 2021;8(6):ofab156. DOI: 10.1093/ofid/ofab156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab156</ArticleId><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, et al. The IL-1beta, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 2022;3(6):100663. DOI: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022;23(2):210&#x2013;216. DOI: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 2021. DOI: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K, Peluso MJ, Thomas R, et al. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv 2023. DOI: 10.1101/2023.02.09.527892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.02.09.527892</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Bonham KS, Anam FA, et al. Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nat Commun 2023;14(1):4201. DOI: 10.1038/s41467-023-40012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40012-7</ArticleId><ArticleId IdType="pmc">PMC10349085</ArticleId><ArticleId IdType="pubmed">37452024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A, Vlok M, Turner S, et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol 2022;21(1):190. DOI: 10.1186/s12933-022-01623-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01623-4</ArticleId><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol 2022;21(1):148. DOI: 10.1186/s12933-022-01579-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB. Prevalence of readily detected amyloid blood clots in &#x2018;unclotted&#x2019; Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report. Cardiovasc Diabetol 2020;19(1):193. DOI: 10.1186/s12933-020-01165-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01165-7</ArticleId><ArticleId IdType="pmc">PMC7670290</ArticleId><ArticleId IdType="pubmed">33203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 2021;20(1):172. DOI: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens 2021;10(6). DOI: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest 2023;133(3). DOI: 10.1172/JCI163669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky A, Wang CY, Saxena A, et al. Autoantigen profiling reveals a shared post-COVID signature in fully recovered and Long COVID patients. medRxiv 2023. DOI: 10.1101/2023.02.06.23285532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.02.06.23285532</ArticleId><ArticleId IdType="pmc">PMC10393220</ArticleId><ArticleId IdType="pubmed">37288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Ramonell RP, Haddad NS, et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature 2022;611(7934):139&#x2013;147. DOI: 10.1038/s41586-022-05273-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05273-0</ArticleId><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K, Jamil R, Chowdhury A, et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J 2023;61(1). DOI: 10.1183/13993003.00970-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00970-2022</ArticleId><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesch F, Ehm F, Vivirito A, et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol 2023. DOI: 10.1007/s10067-023-06670-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-023-06670-0</ArticleId><ArticleId IdType="pmc">PMC10497688</ArticleId><ArticleId IdType="pubmed">37335408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CJ. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine 2023;56:101783. DOI: 10.1016/j.eclinm.2022.101783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101783</ArticleId><ArticleId IdType="pmc">PMC9830133</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591(7851):639&#x2013;644. DOI: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology 2022;163(2):495&#x2013;506 e8. DOI: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) 2022;3(6):371&#x2013;387 e9. DOI: 10.1016/j.medj.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis 2023;76(3):e487&#x2013;e490. DOI: 10.1093/cid/ciac722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 2022;612(7941):758&#x2013;763. DOI: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CCL, Goh D, Lim X, et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 2022;71(1):226&#x2013;229. DOI: 10.1136/gutjnl-2021-324280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V, Mahajan A, Spikes L, et al. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol 2023;95(2):e28568. DOI: 10.1002/jmv.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28568</ArticleId><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG, Mustapic M, et al. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann Neurol 2022;91(6):772&#x2013;781. DOI: 10.1002/ana.26350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26350</ArticleId><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif ZA, Gomez CR, Connors TJ, Henrich TJ, Reeves WB, Force RMPT. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 2023;12. DOI: 10.7554/eLife.86002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86002</ArticleId><ArticleId IdType="pmc">PMC10032659</ArticleId><ArticleId IdType="pubmed">36947108</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res 2022;241:1&#x2013;12. DOI: 10.1016/j.trsl.2021.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.11.006</ArticleId><ArticleId IdType="pmc">PMC8588584</ArticleId><ArticleId IdType="pubmed">34780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrich TJ, Hsue PY, VanBrocklin H. Seeing Is Believing: Nuclear Imaging of HIV Persistence. Front Immunol 2019;10:2077. (In eng). DOI: 10.3389/fimmu.2019.02077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02077</ArticleId><ArticleId IdType="pmc">PMC6751256</ArticleId><ArticleId IdType="pubmed">31572355</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrich TJ, Jones T, Beckford-Vera D, Price PM, VanBrocklin HF. Total-Body PET Imaging in Infectious Diseases. PET Clin 2021;16(1):89&#x2013;97. DOI: 10.1016/j.cpet.2020.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpet.2020.09.011</ArticleId><ArticleId IdType="pmc">PMC10270309</ArticleId><ArticleId IdType="pubmed">33160926</ArticleId></ArticleIdList></Reference><Reference><Citation>Verger A, Barthel H, Tolboom N, et al. 2-[(18)F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee. Eur J Nucl Med Mol Imaging 2022;49(11):3599&#x2013;3606. DOI: 10.1007/s00259-022-05913-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05913-7</ArticleId><ArticleId IdType="pmc">PMC9286958</ArticleId><ArticleId IdType="pubmed">35840817</ArticleId></ArticleIdList></Reference><Reference><Citation>Debs P, Khalili N, Solnes L, et al. Post-COVID-19 Brain [(18)F] FDG-PET Findings: A Retrospective Single-Center Study in the United States. AJNR Am J Neuroradiol 2023;44(5):517&#x2013;522. DOI: 10.3174/ajnr.A7863.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A7863</ArticleId><ArticleId IdType="pmc">PMC10171380</ArticleId><ArticleId IdType="pubmed">37105680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci R, Cuffaro L, Capozza A, et al. Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19. J Neurol 2023;270(4):1823&#x2013;1834. DOI: 10.1007/s00415-022-11543-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11543-8</ArticleId><ArticleId IdType="pmc">PMC9873215</ArticleId><ArticleId IdType="pubmed">36692636</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini AL, Carli G, Kiferle L, et al. Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients. Eur J Nucl Med Mol Imaging 2022;50(1):90&#x2013;102. DOI: 10.1007/s00259-022-05942-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05942-2</ArticleId><ArticleId IdType="pmc">PMC9388976</ArticleId><ArticleId IdType="pubmed">35984451</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LL, van de Burgt A, Smit F, et al. Investigating the potential added value of [ 18 F]FDG-PET/CT in long COVID patients with persistent symptoms: a proof of concept study. Nucl Med Commun 2023;44(6):495&#x2013;501. DOI: 10.1097/MNM.0000000000001689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MNM.0000000000001689</ArticleId><ArticleId IdType="pmc">PMC10171287</ArticleId><ArticleId IdType="pubmed">36951877</ArticleId></ArticleIdList></Reference><Reference><Citation>Goehringer F, Bruyere A, Doyen M, et al. Brain (18)F-FDG PET imaging in outpatients with post-COVID-19 conditions: findings and associations with clinical characteristics. Eur J Nucl Med Mol Imaging 2023;50(4):1084&#x2013;1089. DOI: 10.1007/s00259-022-06013-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-06013-2</ArticleId><ArticleId IdType="pmc">PMC9628394</ArticleId><ArticleId IdType="pubmed">36322190</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Nardo L, Spencer BA, et al. Total-Body Multiparametric PET Quantification of (18) F-FDG Delivery and Metabolism in the Study of COVID-19 Recovery. medRxiv 2023. DOI: 10.1101/2023.03.26.23287673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.26.23287673</ArticleId><ArticleId IdType="pmc">PMC10626370</ArticleId><ArticleId IdType="pubmed">37591539</ArticleId></ArticleIdList></Reference><Reference><Citation>Omidvari N, Jones T, Price PM, et al. First-in-human immunoPET imaging of COVID-19 convalescent patients using dynamic total-body PET and a CD8-targeted minibody. medRxiv 2023. DOI: 10.1101/2023.03.14.23287121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.14.23287121</ArticleId><ArticleId IdType="pmc">PMC10569706</ArticleId><ArticleId IdType="pubmed">37824612</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Kelly JD, Lu S, et al. Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infect Dis 2022;9(2):ofab640. DOI: 10.1093/ofid/ofab640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab640</ArticleId><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi J, Lam T, Goth SR, et al. Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. Cancer Res 2019;79(13):3455&#x2013;3465. DOI: 10.1158/0008-5472.CAN-19-0267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-19-0267</ArticleId><ArticleId IdType="pmc">PMC6606349</ArticleId><ArticleId IdType="pubmed">31064845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronald JA, Kim BS, Gowrishankar G, et al. A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res 2017;77(11):2893&#x2013;2902. DOI: 10.1158/0008-5472.CAN-16-2953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2953</ArticleId><ArticleId IdType="pmc">PMC5505323</ArticleId><ArticleId IdType="pubmed">28572504</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi J, Duan H, Yaghoubi S, et al. Biodistribution of a Mitochondrial Metabolic Tracer, [(18)F]F-AraG, in Healthy Volunteers. Mol Imaging 2022;2022:3667417. DOI: 10.1155/2022/3667417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/3667417</ArticleId><ArticleId IdType="pmc">PMC9400547</ArticleId><ArticleId IdType="pubmed">36072652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yim JJ, Park J. Pulmonary function and chest computed tomography abnormalities 6&#x2013;12 months after recovery from COVID-19: a systematic review and meta-analysis. Respir Res 2022;23(1):233. DOI: 10.1186/s12931-022-02163-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02163-x</ArticleId><ArticleId IdType="pmc">PMC9446643</ArticleId><ArticleId IdType="pubmed">36068582</ArticleId></ArticleIdList></Reference><Reference><Citation>Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS, Gambhir SS. Synthesis of 2&#x2019;-deoxy-2&#x2019;-[18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET. Mol Imaging Biol 2011;13(5):812&#x2013;8. DOI: 10.1007/s11307-010-0414-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11307-010-0414-x</ArticleId><ArticleId IdType="pubmed">20838911</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez CO, , Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res
2002;62(11):3100&#x2013;5. (https://www.ncbi.nlm.nih.gov/pubmed/12036920).</Citation><ArticleIdList><ArticleId IdType="pubmed">12036920</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti C, Jr., Levi J, Huynh TL, et al. Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using (18)F-FAraG PET and MRI. J Nucl Med 2022;63(1):140&#x2013;146. DOI: 10.2967/jnumed.120.259325.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.120.259325</ArticleId><ArticleId IdType="pmc">PMC8717198</ArticleId><ArticleId IdType="pubmed">33837066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010;31(6):496&#x2013;505. (In eng). DOI: S0887&#x2013;2171(10)00088&#x2013;0 [pii] 10.1053/j.sult.2010.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.sult.2010.10.001</ArticleId><ArticleId IdType="pmc">PMC3026294</ArticleId><ArticleId IdType="pubmed">21147377</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet AM, Reynolds CA, Eriksson UK, et al. Genetic association of sequence variants near AGER/NOTCH4 and dementia. J Alzheimers Dis 2011;24(3):475&#x2013;84. DOI: 10.3233/JAD-2011-101848.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101848</ArticleId><ArticleId IdType="pmc">PMC3477600</ArticleId><ArticleId IdType="pubmed">21297263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LC, Almazan G. Cdon, a cell surface protein, mediates oligodendrocyte differentiation and myelination. Glia 2016;64(6):1021&#x2013;33. DOI: 10.1002/glia.22980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22980</ArticleId><ArticleId IdType="pubmed">26988125</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas-Franco D, Kalra R, Draper I, Pacak CA, Asakura A, Kang PB. The Notch signaling pathway in skeletal muscle health and disease. Muscle Nerve 2022;66(5):530&#x2013;544. DOI: 10.1002/mus.27684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27684</ArticleId><ArticleId IdType="pmc">PMC9804383</ArticleId><ArticleId IdType="pubmed">35968817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogasawara M, Nishino I. A review of core myopathy: central core disease, multiminicore disease, dusty core disease, and core-rod myopathy. Neuromuscul Disord 2021;31(10):968&#x2013;977. DOI: 10.1016/j.nmd.2021.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2021.08.015</ArticleId><ArticleId IdType="pubmed">34627702</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakovcevski M, Akbarian S, Di Benedetto B. Pharmacological modulation of astrocytes and the role of cell type-specific histone modifications for the treatment of mood disorders. Curr Opin Pharmacol 2016;26:61&#x2013;6. DOI: 10.1016/j.coph.2015.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2015.10.002</ArticleId><ArticleId IdType="pmc">PMC4716874</ArticleId><ArticleId IdType="pubmed">26515273</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med 2022;3(6):371&#x2013;387 e9. DOI: 10.1016/j.medj.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med 2022;20(1):26. DOI: 10.1186/s12916-021-02228-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Wang B, Gao H, Gao L, Hua R, Xu JD. ACE2 in the Gut: The Center of the 2019-nCoV Infected Pathology. Front Mol Biosci 2021;8:708336. DOI: 10.3389/fmolb.2021.708336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.708336</ArticleId><ArticleId IdType="pmc">PMC8493804</ArticleId><ArticleId IdType="pubmed">34631794</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, et al. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front Immunol 2021;12:746021. DOI: 10.3389/fimmu.2021.746021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID Data Tracker.
Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2023, July
23. https://covid.cdc.gov/covid-data-tracker.</Citation></Reference><Reference><Citation>Vasquez JJ, Aguilar-Rodriguez BL, Rodriguez L, et al. CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. Pathog 840 Immun 2019;4(1):147&#x2013;160. (In eng). DOI: 10.20411/pai.v4i1.271 pai.v4i1.271 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v4i1.271</ArticleId><ArticleId IdType="pmc">PMC6508427</ArticleId><ArticleId IdType="pubmed">31139759</ArticleId></ArticleIdList></Reference><Reference><Citation>Park LM, Lannigan J, Jaimes MC. OMIP-069: Forty-Color Full Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood. Cytometry A 844 2020;97(10):1044&#x2013;1051. DOI: 10.1002/cyto.a.24213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24213</ArticleId><ArticleId IdType="pmc">PMC8132182</ArticleId><ArticleId IdType="pubmed">32830910</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>